BlackRock Trims Arrowhead Pharma Stake to 6.6%
Ticker: ARWR · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 879407
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals, stake-change
TL;DR
**BlackRock still owns a big chunk of Arrowhead Pharma, but slightly less than before.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Arrowhead Pharmaceuticals Inc. As of December 31, 2023, BlackRock reported beneficial ownership of 7,000,000 shares of Arrowhead's Common Stock, representing 6.6% of the company. This is an update to their previous filing, indicating a slight decrease in their stake from 7.1% reported in their last filing on February 1, 2023. This matters to investors because BlackRock, a major institutional investor, still holds a significant position, signaling continued confidence in Arrowhead Pharmaceuticals, despite a minor reduction.
Why It Matters
This filing shows that a major institutional investor, BlackRock, continues to hold a substantial stake in Arrowhead Pharmaceuticals, which can be seen as a vote of confidence, even with a slight reduction in their holdings.
Risk Assessment
Risk Level: low — The filing indicates a minor adjustment in a large institutional holding, which typically carries low immediate risk for the average investor.
Analyst Insight
A smart investor would note BlackRock's continued, though slightly reduced, institutional support for Arrowhead Pharmaceuticals, but would not make investment decisions based solely on this minor change. Further research into Arrowhead's fundamentals and pipeline would be prudent.
Key Numbers
- 7,000,000 — Shares Beneficially Owned (BlackRock's total shares in Arrowhead Pharmaceuticals as of December 31, 2023.)
- 6.6% — Percentage of Class (BlackRock's ownership percentage of Arrowhead Pharmaceuticals' Common Stock.)
- December 31, 2023 — Reporting Date (The date for which the ownership information is reported.)
- January 23, 2024 — Filing Date (The date the amended SC 13G/A was filed.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Arrowhead Pharmaceuticals Inc. (company) — the subject company in which BlackRock holds shares
- 7,000,000 shares (dollar_amount) — the number of shares beneficially owned by BlackRock as of December 31, 2023
- 6.6% (dollar_amount) — the percentage of Arrowhead Pharmaceuticals' Common Stock beneficially owned by BlackRock as of December 31, 2023
- December 31, 2023 (dollar_amount) — the date of the event requiring the filing of this statement
- January 23, 2024 (dollar_amount) — the filing date of the SC 13G/A amendment
Forward-Looking Statements
- BlackRock will maintain a significant, albeit potentially fluctuating, stake in Arrowhead Pharmaceuticals Inc. throughout 2024. (BlackRock Inc.) — medium confidence, target: December 31, 2024
- Arrowhead Pharmaceuticals Inc.'s stock price will not be significantly impacted by this minor adjustment in BlackRock's holding. (Arrowhead Pharmaceuticals Inc.) — high confidence, target: March 31, 2024
FAQ
What is the purpose of this SC 13G/A filing?
This SC 13G/A filing is an amendment (Amendment No: 2) by BlackRock Inc. to update its beneficial ownership of Common Stock in Arrowhead Pharmaceuticals Inc. as of December 31, 2023, under Rule 13d-1(b).
How many shares of Arrowhead Pharmaceuticals Inc. does BlackRock Inc. beneficially own as of December 31, 2023?
As of December 31, 2023, BlackRock Inc. beneficially owns 7,000,000 shares of Common Stock in Arrowhead Pharmaceuticals Inc.
What percentage of Arrowhead Pharmaceuticals Inc.'s Common Stock does BlackRock Inc. own?
BlackRock Inc. owns 6.6% of the Common Stock of Arrowhead Pharmaceuticals Inc. as of December 31, 2023.
When was the event date that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
What is the CUSIP number for Arrowhead Pharmaceuticals Inc.'s Common Stock?
The CUSIP number for Arrowhead Pharmaceuticals Inc.'s Common Stock is 04280A100.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding ARROWHEAD PHARMACEUTICALS, INC. (ARWR).